Proton Pump Inhibitor Therapy and Risk of All-Cause Mortality

Read Article

To determine the association between proton pump inhibitors (PPIs) use and mortality was evaluated by a prospective analysis of 440,840 UK residents and 13,154 deaths. The evaluation was carried out to determine the associations with multivariate Cox regression. 

After adjusting for confounders, such as health status and longstanding diseases, the regular use of PPIs was not associated with an increased risk of all-cause mortality and mortality due to neoplasms, circulatory system diseases, respiratory system diseases, digestive system diseases, external causes and other causes. 

It was concluded that regular use of PPIs was not associated with increased risk of all-cause and cause-specific mortality. 

He, Q., Xia, B., Meng, W., et al.  “No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality:  A PopulationBased Cohort of 0.44 Million Participants.” American Journal of Gastroenterology, Vol. 116, November 2021, pp. 2286-2291

Download Tables, Images & References